血清戊糖素及可溶性晚期糖基化终末产物受体与老年2型糖尿病患者肌少症的相关性研究

doi:10.3969/j.issn.1003-9198.2025.12.012

摘要/Abstract

摘要： 目的探讨血清戊糖素及可溶性晚期糖基化终末产物受体(sRAGE)与老年T2DM患者肌少症的相关性。方法选取2024年6月至2025年5月保定市第一中心医院内分泌科收治的136例年龄≥60岁的T2DM患者为研究对象,根据其是否合并肌少症分为肌少症组(n=42)和非肌少症组(n=94)。收集2组一般资料及相关实验室指标,采用酶联免疫吸附法检测血清戊糖素及sRAGE水平。采用多因素logistic回归分析老年T2DM合并肌少症的相关因素。采用ROC曲线分析血清戊糖素和sRAGE预测老年T2DM患者合并肌少症的价值。结果肌少症组年龄、糖尿病病程、HbA1c、戊糖素水平显著高于非肌少症组,BMI、白蛋白(ALB)、TG、sRAGE水平显著低于非肌少症组(P＜0.05)。多因素logistic回归分析结果显示,低BMI(OR=0.767, 95%CI: 0.634～0.929)、高水平戊糖素(OR=1.018, 95%CI: 1.007～1.029)、低水平sRAGE (OR=0.994, 95%CI: 0.991～0.997)为老年T2DM发生肌少症的独立危险因素(P＜0.05)。血清戊糖素联合sRAGE预测老年T2DM合并肌少症的曲线下面积为0.881(95%CI:0.815～0.947),高于两指标单独的预测价值(AUC=0.798、0.795,Z=2.094、2.552,均P＜0.05)。结论老年T2DM患者血清戊糖素、sRAGE水平与肌少症的发生密切相关,二者联合检测对预测老年T2DM患者是否合并肌少症具有良好的效能,有望作为辅助诊断的生物标志物。

关键词: 2型糖尿病, 肌少症, 戊糖素, 可溶性晚期糖基化终末产物受体

Abstract: Objective To investigate the association of serum levels of pentosidine, soluble receptor for advanced glycation end products (sRAGE) with sarcopenia in elderly patients with type 2 diabetes mellitus (T2DM). Methods A total of 136 T2DM patients aged over 60 years admitted to Department of Endocrinology of Baoding NO.1 Central Hospital from June 2024 to May 2025 were enrolled and divided into sarcopenic group (42 cases) and non-sarcopenic group (94 cases) based on the Asian Working Group for Sarcopenia criteria. The general information and biochemical indicators were collected, and serum levels of pentosidine and sRAGE were measured by enzyme-linked immunosorbent assay (ELISA).Multivariate logistic regression was applied to identify independent factors associated with sarcopenia in the elderly T2DM patients. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the predictive value of serum pentosidine and sRAGE for sarcopenia in the elderly T2DM patients. Results Compared with the non-sarcopenic group, the patients in sarcopenic group had significantly higher age, diabetes duration, glycated hemoglobin (HbA1c), and serum pentosidine levels, while their body mass index (BMI), albumin (ALB), triglyceride (TG), and sRAGE levels were lower (P<0.05). Logistic regression analysis showed that low BMI(OR=0.767, 95%CI: 0.634-0.929), high pentosidine levels (OR=1.018, 95%CI: 1.007-1.029), and low sRAGE levels(OR=0.994, 95%CI: 0.991-0.997)were independent risk factors for sarcopenia in elderly T2DM patients (P<0.05). The area under the ROC curve for the combination of serum pentosidine and sRAGE was 0.881 (95%CI: 0.815-0.947) in predicting sarcopenia in elderly patients with T2DM,which was significantly better than that of either single indicator (P<0.05). Conclusions Serum levels of pentosidine and sRAGE are closely related to sarcopenia in elderly T2DM patients. The combination of the two indicators has excellent efficacy in identifying sarcopenia in elderly T2DM patients, suggesting their potential utility as auxiliary diagnostic biomarkers.

Key words: type 2 diabetes mellitus, sarcopenia, pentosidine, soluble receptor for advanced glycation end products

中图分类号:

董越华, 辛欢欢, 姚琪, 王寒, 王翯. 血清戊糖素及可溶性晚期糖基化终末产物受体与老年2型糖尿病患者肌少症的相关性研究[J]. 实用老年医学, 2025, 39(12): 1248-1252.

DONG Yuehua, XIN Huanhuan, YAO Qi, WANG Han, WANG He. Association of serum pentosidine and sRAGE with sarcopenia in elderly patients with type 2 diabetes[J]. Practical Geriatrics, 2025, 39(12): 1248-1252.

参考文献

[1] 国家老年医学中心, 中华医学会老年医学分会, 中国老年保健协会糖尿病专业委员会, 等. 中国老年糖尿病诊疗指南(2024版)[J]. 中华老年医学杂志, 2024, 43(2): 105-147.
[2] CRUZ-JENTOFT A J, SAYER A A. Sarcopenia[J]. Lancet, 2019, 393(10191): 2636-2646.
[3] VOULGARIDOU G, TYROVOLAS S, DETOPOULOU P, et al. Diagnostic criteria and measurement techniques of sarcopenia: a critical evaluation of the up-to-date evidence[J]. Nutrients, 2024, 16(3): 436.
[4] SUN Y, ZHANG Z, WANG Y, et al. Hidden pathway: the role of extracellular matrix in type 2 diabetes mellitus-related sarcopenia[J]. Front Endocrinol, 2025, 16: 1560396.
[5] PETERMANN-ROCHA F, BALNTZI V, GRAY S R, et al. Global prevalence of sarcopenia and severe sarcopenia: a systematic review and meta-analysis[J]. J Cachexia Sarcopenia Muscle, 2022, 13(1): 86-99.
[6] ALFARO-ALVARADO F A, ROSAS-BARRIENTOS J V, OCHARAN-HERNÁNDEZ M E, et al. Association between sarcopenia and poor glycemic control in older adults with type 2 diabetes mellitus[J]. Diseases, 2023, 11(4): 175.
[7] 王金涛, 胡坚. 老年人2型糖尿病与肌少症的关系研究进展[J]. 实用老年医学, 2024, 38(5): 529-532.
[8] SCHRÖTER D, HÖHN A. Role of advanced glycation end products in carcinogenesis and their therapeutic implications[J]. Curr Pharm Des, 2018, 24(44): 5245-5251.
[9] 于家敏, 王亚昕, 周健. 晚期糖基化终末产物与糖尿病慢性并发症的研究进展[J]. 中华糖尿病杂志, 2023, 15(11):1146-1151.
[10] TANAKA K, KANAZAWA I, SUGIMOTO T. Elevated serum pentosidine and decreased serum IGF-I levels are associated with loss of muscle mass in postmenopausal women with type 2 diabetes mellitus[J]. Exp Clin Endocrinol Diabetes, 2016, 124(3): 163-166.
[11] VASILJ M, GONI L, GAYOSO L, et al. Correlation between serum advanced glycation end products and dietary intake of advanced glycation end products estimated from home cooking and food frequency questionnaires[J]. Nutr Metab Cardiovasc Dis, 2023, 33(9): 1768-1777.
[12] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华糖尿病杂志, 2021, 13(4):315-409.
[13] CHEN L K, WOO J, ASSANTACHAI P, et al. Asian working group for sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment[J]. J Am Med Dir Assoc, 2020, 21(3): 300-307.e2.
[14] GUO Z, LI H, JIANG S, et al. The role of AGEs in muscle ageing and sarcopenia[J]. Bone Joint Res, 2025, 14(3): 185-198.
[15] MATSUMOTO S, OCHI M, AKECHI Y, et al. Dermal advanced glycation end-product accumulation is associated with sarcopenia-related measures in middle-aged and older men[J]. Arch Gerontol Geriatr, 2022, 101: 104704.
[16] 周敏, 杨爱霞, 郭雪娟, 等. 血清骨硬化蛋白及戊糖素与2型糖尿病肾病患者并发肌少症的关系[J]. 疑难病杂志, 2024, 23(5): 563-568.
[17] STEENBEKE M, SPEECKAERT R, DESMEDT S, et al. The role of advanced glycation end products and its soluble receptor in kidney diseases[J]. Int J Mol Sci, 2022, 23(7): 3439.
[18] JIANG Y, XU B, ZHANG K, et al. The association of lipid metabolism and sarcopenia among older patients: a cross-sectional study[J]. Sci Rep, 2023, 13(1): 17538.
[19] TANG W, YU J, YANG K, et al. Association between sarcopenia and components of metabolic syndrome among Chinese older adults: a population-based longitudinal study using CHARLS[J]. BMC Public Health, 2025, 25(1): 2823.
[20] GONG H, LIU Y, LYU X, et al. Lipoprotein subfractions in patients with sarcopenia and their relevance to skeletal muscle mass and function[J]. Exp Gerontol, 2022, 159: 111668.
[21] ABE S, EZAKI O, SUZUKI M. Medium-chain triglycerides (8: 0 and 10: 0) are promising nutrients for sarcopenia: a randomized controlled trial[J]. Am J Clin Nutr, 2019, 110(3): 652-665.
[22] WU X, LI X, XU M, et al. Sarcopenia prevalence and associated factors among older Chinese population: findings from the China Health and Retirement Longitudinal Study[J]. PLoS One, 2021, 16(3): e0247617.